CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma (Q37666309)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 September 2013

Language	Label	Description	Also known as
English	CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma	scientific article published on 26 September 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

author name string

J Chu

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

D M Benson

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

S He

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

T Hughes

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

J Zhang

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

H Mao

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

L Yi

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

K Ghoshal

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

X He

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

S M Devine

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

X Zhang

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

M A Caligiuri

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

C C Hofmeister

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

J Yu

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

publication date

26 September 2013

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

28

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

917-927

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

NK cell-based immunotherapy for malignant diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

MicroRNAs activate natural killer cells through Toll-like receptor signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Human NK cell lytic granules and regulation of their exocytosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

The role of natural killer cells in immunity against multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

IFN-γ inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T-cell apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Treatment of newly diagnosed myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Bone marrow microenvironment and the identification of new targets for myeloma therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Natural killer or dendritic: what's in a name?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

BCMA is essential for the survival of long-lived bone marrow plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Regulation of macrophage activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

6 September 2017

Zoom Zoom: racing CARs for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

14 September 2017

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

14 September 2017

Natural killer cells activated in a human mixed lymphocyte response culture identified by expression of Leu-11 and class II histocompatibility antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

25 June 2018

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

1 September 2018

NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

1 September 2018

Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

1 September 2018

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3967004

1 September 2018

CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4 and CD8 T cells in an antitumor cell attack

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Graft-versus-myeloma effect: proof of principle

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CS1-directed monoclonal antibody therapy for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of CD69 expression on human natural killer cells: differential involvement of protein kinase C and protein tyrosine kinases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming

1 reference

https://pubmed.ncbi.nlm.nih.gov/24067492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2013.279

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24067492 AND SRC:MED&resulttype=core&format=json

14 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37666309&oldid=2230857142"